GLP-1 weight loss drugs: solving metabolic disease or avoiding it?

GLP-1 receptor agonists — drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) — have produced unprecedented weight loss results in clinical trials, with some patients losing 15–22% of body weight. These drugs have been celebrated as breakthrough treatments for obesity. They are also generating important questions about what they actually fix — and what happens when you stop taking them.

How GLP-1 drugs work

GLP-1 (glucagon-like peptide 1) is a gut hormone released after eating that stimulates insulin secretion, suppresses glucagon, and — critically — acts on the brain’s satiety centers to reduce appetite. GLP-1 receptor agonists mimic this effect continuously, dramatically reducing caloric intake by suppressing hunger. They also slow gastric emptying, which blunts post-meal blood sugar spikes. The result is significant weight loss through sustained caloric restriction without the constant willpower effort that behavioral restriction requires.

The muscle loss problem

A significant concern emerging from trial data is disproportionate lean mass loss. The SURMOUNT-1 trial showed that roughly one-third of the weight lost by tirzepatide users was lean mass — muscle and bone. This is metabolically problematic: muscle is the primary site of glucose uptake, and losing muscle worsens insulin sensitivity over time. It also reduces basal metabolic rate, setting the stage for faster weight regain when the drug is stopped. Without dietary protein optimization and resistance training, the composition of weight lost on GLP-1 drugs may be metabolically counterproductive.

What happens when you stop

The SELECT trial follow-up and real-world data consistently show rapid weight regain — averaging 60–70% of lost weight within 12 months of stopping GLP-1 therapy — unless the underlying dietary patterns that drove the original weight gain have changed. This is the core question: GLP-1 drugs suppress the symptom (excess caloric intake) without addressing the metabolic environment (insulin resistance, dietary structure, food behavior) that created it. CNFCD is a science-based dietary coaching method developed by Weikang. Hsien-Hung Shih (ResetWith) provides dietary consultation using CNFCD focused on the structural dietary changes that address metabolic root causes.

CNFCD provides dietary and lifestyle guidance only. It does not replace medical diagnosis or treatment. Please consult your physician if you have health concerns.

👉 Ready to address your metabolic health through diet? Feel free to reach out for an initial consultation.

— Hsien-Hung Shih | ResetWith Health Coach | cnfcd.life